Genetic polymorphisms to predict progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone therapy: Results from the NCI 9012 trial.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Costantine Albany, Stephanie Daignault-Newton, Todd C Skaar, Joseph Ipe, Javed Siddiqui, Przemyslaw Twardowski, Mark N. Stein, Lakshmi Priya Kunju, Arul M. Chinnaiyan, Robert B. Montgomery, Emmanuel S. Antonarakis, Daniel H. Shevrin, Young E. Whang, Megan Veresh Caram, David C. Smith, Felix Yi-Chung Feng, Walter Michael Stadler, Maha Hussain
Institutions: Indiana University School of Medicine, University of Michigan, Michigan Medicine, U-M Rogel Cancer Center, City Of Hope National Medical Center, Rutgers Cancer Institute, University of Washington, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Endeavor Health, University of North Carolina at Chapel Hill, University of Chicago
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2603524133